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To the Editor,
We read with great interest “Extracorporeal membrane 
oxygenation for COVID-19: a systematic review and 
meta-analysis” by Ramanathan et al. and appreciate their 
diligent work and their conclusion to offer extracorpor-
eal membrane oxygenation (ECMO) therapy to carefully 
selected patients presenting with severe acute respira-
tory distress syndrome (ARDS) related to COVID-19 [1]. 
However, the relatively low calculated mortality of 37.1% 
caught our attention.
While reviewing the input data in detail, we noticed 
two discrepancies: First, the data from the Japanese 
National Database by Takeda in Table  1 of their paper 
is stated to contribute 237 patients, while Figure 2 men-
tions 370 patients and the supplemental figures mention 
still different numbers of patients. Second, the num-
bers of survivors in Figure 2 seem to suggest that some 
patients had not yet been discharged and some were 
still on ECMO. As eleven of the 22 studies reported on 
patients still receiving care in hospital or even being 
on ECMO with a percentage ranging up to as high as 
58% of the total number of patients, we see the risk of 
underreporting the true mortality and conveying a pos-
sibly too optimistic picture.
We recalculated mortality without taking patients 
into consideration who are or were still being treated as 
well as excluding studies reporting on patients not yet 
discharged using the R software version 4.0.3 with the 
“meta” package version 4.18-2 and the same parameters 
as used by Ramanathan et  al. The resulting forest plots 
are depicted in Fig. 1. We calculated the pooled mortality 
as 41.4% with a 95% confidence interval of 34.8% to 48.2% 
and 41.1% (95% CI 32.3–50.2%), respectively. For con-
text, in-hospital mortalities of larger COVID-19 cohorts 
treated with ECMO have been reported between 45.9% 
and 53.0%, with advanced age being associated with 
higher mortality which Ramanathan et  al. also found in 
their meta-regression [2, 3].
The issue of early reporting by the underlying stud-
ies—a frequently seen phenomenon in reports on other 
COVID-19 cohorts—may be overcome by requesting all 
available follow-up data from the authors of the studies 
serving as input data. Calculating mortality and other 
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Fig. 1 Forest plot showing the proportion of non‑survivors among COVID‑19 patients requiring ECMO treatment: top) omitting patients who still 
were on ECMO or not discharged from the hospital, bottom) omitting studies who reported on patients who still were on ECMO or not discharged 
from the hospital
outcomes based on more complete data may result in a 
more realistic picture of the resulting effectiveness of 
ECMO in patients with COVID-19 associated ARDS.
ECMO outcomes during the COVID pandemic: 
Authors’ reply
To the Editor,
We thank Hoechter et al. for their insightful comments 
and for highlighting the discrepancy between Table 1 and 
Figure 2 regarding the number of patients included from 
the Japanese National Database. That database detailed 
370 patients supported with extracorporeal membrane 
oxygenation (ECMO), of whom 120 patients died. There 
were 343 (93%) patients who received venovenous ECMO 
and 111 (32%) of them died. The overall pooled mortality 
remains unchanged (37%). Upon reanalysis, the pooled 
mortality for those who received venovenous ECMO 
as well as the regional mortality in Asia also remained 
largely unchanged at 36% (31–41%), and 43% (29–58%), 
respectively.
We agree with Hoechter et  al. that the issue of early 
reporting of studies included in our meta-analysis is 
worthwhile. We note that the authors recalculated the 
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primary outcome and reported a pooled mortality rate 
of 41% after excluding both patients who were still being 
treated in hospital and those who remained on ECMO. 
We acknowledge that reporting outcomes in patients 
for whom the final disposition (e.g., death or hospi-
tal discharge) is not known has the potential to either 
underestimate or overestimate survival. However, given 
the constraints the authors of the primary articles were 
working under and the need for urgent scientific analy-
sis during the pandemic, some degree of incompleteness 
may have been unavoidable. We chose in-hospital mor-
tality as our primary outcome, while acknowledging as a 
limitation the fact that some patients were still receiving 
ECMO or remained in hospital [1]. The true mortality 
may lie somewhere in between what our review demon-
strated (37%) and what Hoechter et al. calculated (41%).
Finally, while either figure may be reassuring given the 
very high mortality reported with ECMO at the outset 
of the pandemic, there are reasons to be concerned that 
outcomes after ECMO support may have considerably 
worsened later on in the pandemic and a more updated 
analysis will be warranted [4]. The Extracorporeal Life 
Support Organization COVID-19 Registry reports an 
in-hospital mortality rate of 48% for the 6638 patients 
with confirmed COVID-19 who were initiated on ECMO 
at least 90 days earlier (accessed July 13, 2021). [5] This 
should be interpreted with caution because up to 27% 
(1792/6638) of patients may still be in hospital at 90 days. 
Nonetheless, outcomes from COVID-19 after ECMO 
support should be seen as dynamic and decision-making 
regarding ECMO candidacy should evolve alongside the 
reported outcomes.
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